PoliCOV: Police COVID-19 Serosurvey

Sponsor
University of Bern (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04643444
Collaborator
Interregionale Blutspende SRK Bern (Other)
1,000
1
15.7
63.8

Study Details

Study Description

Brief Summary

The investigators aim to determine the immune status of the employees of the cantonal police of Bern against SARS-CoV-2 over a period of 1 year, and to investigate the risk profile of the study participants and their risk of SARS-CoV-2 exposure in their working and private environments, as well as to evaluate the use of personal protective equipment at potential exposure instances.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Blood sampling
  • Other: Online Questionnaire

Detailed Description

  1. To determine the extent of infection with seroprevalence data in the special population of police officers of the canton Bern.

  2. To determine risk factors for infection by comparing the proportion of seropositivity (infected versus noninfected individuals). The investigators hypothesize that police officers with fieldwork activity will have a higher seroprevalence than will office and administration personnel. The investigators hypothesize that working in the city of Bern will be associated with a higher seroprevalence than will working in other geographic areas of the canton (i.e. rural area).

  3. To monitor COVID-19 antibody titres and neutralizing capacity over time and to associate them with reinfection rates and infection-free intervals in police officers after accidental contact with a proven COVID-19 case. The investigators hypothesize that in seropositive individuals, there will be a decreasing dynamic of antibody titres over the one-year study period, and hence, a decrease of neutralizing capacity.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Police Officer COVID-19 Seroprevalence Survey in the Canton of Bern, Switzerland
Actual Study Start Date :
Feb 9, 2021
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Seroprevalence [One year]

    The variable of primary interest is COVID-19 seropositivity. This variable is measured at five time points over the one-year study period. The following baseline factors may have an influence on the primary endpoint and will be obtained: (i) pre-existing comorbidities, (ii) rural versus city distribution of working place, and (iii) office work versus field work.

Secondary Outcome Measures

  1. Risk profile assessment [One year]

    The investigators will assess the proportion of symptomatic and asymptomatic cases among seropositive participants. The investigators will calculate the attack rate in different subgroup. These include (i) study participants with health-related risk factors (age>50 and age>60 years, diabetes, arterial hypertension, cardiovascular disease, chronic pulmonary disease, immune-compromised status due to host diseases, medical treatment, cancer, obesity), (ii) activity-related subgroups (i.e. fieldwork vs office activity), (iii) geography-related subgroups (i.e. city vs rural areas). In follow-up visits, the antibody titers (i.e. dynamic) and the neutralization capacity will be assessed. Thereby, the investigators will determine the change in serum levels of SARS-CoV-2 antibodies over time in seropositive participants.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Police officers of the cantonal police of Bern volunteering to participate in the study.
Exclusion Criteria:
  • Refusal or inability to give informed consent or contraindication to venepuncture.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Bern, Institute for Infectious Diseases Bern BE Switzerland 3010

Sponsors and Collaborators

  • University of Bern
  • Interregionale Blutspende SRK Bern

Investigators

  • Principal Investigator: Parham Sendi, MD, University of Bern

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Bern
ClinicalTrials.gov Identifier:
NCT04643444
Other Study ID Numbers:
  • 2020-02650
First Posted:
Nov 25, 2020
Last Update Posted:
Feb 16, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Bern
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 16, 2021